| Cancer immunotherapy: broadening the scope of targetable tumours J van den Bulk, EME Verdegaal, NFCC de Miranda Open biology 8 (6), 180037, 2018 | 244 | 2018 |
| γδ T cells are effectors of immunotherapy in cancers with HLA class I defects NL de Vries, J van de Haar, V Veninga, M Chalabi, ME Ijsselsteijn, ... Nature, 1-8, 2023 | 177 | 2023 |
| Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer BJ Hos, MGM Camps, J Bulk, E Tondini, TC Ende, D Ruano, K Franken, ... Oncoimmunology 9 (1), 1673125, 2020 | 77 | 2020 |
| Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression J van den Bulk, NFCC de Miranda, P Ten Dijke Clinical Science 135 (1), 35-52, 2021 | 66 | 2021 |
| Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4 SHBNFCCM Jitske van den Bulk, Els M. E. Verdegaal, Dina Ruano, Marieke E ... Genome Medicine, 2019 | 63 | 2019 |
| Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer EJ Blok, J van den Bulk, NG Dekker-Ensink, R Derr, C Kanters, ... Oncotarget 8 (9), 15610, 2017 | 31 | 2017 |
| CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden J van den Bulk, M van der Ploeg, ME Ijsselsteijn, D Ruano, ... Journal for ImmunoTherapy of Cancer 11 (2), e005887, 2023 | 17 | 2023 |
| Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA BJ Hos, E Tondini, MGM Camps, W Rademaker, J van den Bulk, D Ruano, ... Cell reports 41 (2), 111485, 2022 | 10 | 2022 |
| γδ T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects NL de Vries, J van de Haar, V Veninga, M Chalabi, ME Ijsselsteijn, ... bioRxiv, 2021.10. 14.464229, 2021 | 4 | 2021 |
| Abstract A186: A new strategy to identify and expand tumor-reactive CD8 TILs in human solid tumors T Duhen, R Duhen, R Montler, T Moudgil, J Bulk, BA Fox, SC Chang, ... Cancer Immunology Research 7 (2_Supplement), A186-A186, 2019 | 2 | 2019 |
| gamma delta T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects JV De Haar, NL De Vries, V Veninga, M Chalabi, M Ijsselsteijn, ... ANNALS OF ONCOLOGY 33 (7), S878-S878, 2022 | | 2022 |
| 733MO γδT cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects J Van De Haar, NL de Vries, V Veninga, M Chalabi, M Ijsselsteijn, ... Annals of Oncology 33, S878, 2022 | | 2022 |
| Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development J van den Bulk, D Ruano, ME Ijsselsteijn, M Visser, R van der Breggen, ... CANCER IMMUNOLOGY RESEARCH 7 (2), 2019 | | 2019 |
| Abstract B094: Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development J Bulk, D Ruano, ME Ijsselsteijn, M Visser, R Breggen, KCMJ Peeters, ... Cancer Immunology Research 7 (2_Supplement), B094-B094, 2019 | | 2019 |
| PO-410 Discovery of immunogenic neoantigens for peptide vaccination approaches in murine colorectal cancer B Hos, M Camps, E Tondini, D Ruano, J Van den Bulk, K Franken, ... ESMO Open 3, A390, 2018 | | 2018 |
| Screening for neoantigen-specific CD8+ T cells using thermally-exchanged pMHCI multimers JJ Luimstra, C Heeke, J van den Bulk, B Hos, F Ossendorp, ... approaches to monitor and modulate the adaptive immune system, 163, 0 | | |